Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
- 1 January 2004
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 32 (1) , 28-35
- https://doi.org/10.1016/j.exphem.2003.09.021
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- CTLA4 Blockade Maximizes Antitumor T-Cell Activation by Dendritic Cells Presenting Idiotype Protein or Opsonized Anti-CD20 Antibody-Coated Lymphoma CellsJournal of Immunotherapy, 2002
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantationCytotherapy, 2002
- Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityBlood, 2001
- Rituximab Dose-Escalation Trial in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease statusLeukemia, 2001
- Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemiaBone Marrow Transplantation, 2000
- HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic LeukemiaAnnals of Internal Medicine, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945